Targets › USH2A
1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology; next expected readout Jul 2028.
Involved in hearing and vision as member of the USH2 complex. In the inner ear, required for the maintenance of the hair bundle ankle formation, which connects growing stereocilia in developing cochlear hair cells. (UniProt, O75445)
Open in Phaseline: the race on USH2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Laboratoires Thea | Ultevursen USH2A exon 13 gene therapy | USH2A | Phase 2 | Retinitis Pigmentosa (RP) | Jul 2028 |
Retinitis Pigmentosa (RP) (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.